Codexis to Participate in Upcoming Virtual Healthcare Conferences
Codexis (Nasdaq:CDXS), an enzyme engineering leader, announced its participation in two virtual investment conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Codexis (Nasdaq:CDXS), an enzyme engineering leader, announced its participation in two virtual investment conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will take place on September 13, 2021, featuring an on-demand corporate presentation. Following that, the Cantor Virtual Global Healthcare Conference is scheduled for September 28, 2021, with a fireside chat at 10:40 a.m. ET. Webcasts of both events will be available on the Company's Investor Relations website for 90 days post-event, highlighting Codexis' advancements in synthetic biology and enzyme technology.
Details
News Market Reaction – CDXS
The recorded move for CDXS in the trading session of this news was -0.66%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in two upcoming virtual investment conferences.
The H.C. Wainwright 23rd Annual Global Investment Conference — September 13, 2021 at 7:00 a.m. ET, on-demand corporate presentation
The Cantor Virtual Global Healthcare Conference — September 28, 2021 at 10:40 a.m. ET, fireside chat
Webcasts of the presentations will be available in the Investor Relations section of the Company’s website, http://ir.codexis.com. Replays of the webcasts will be archived for 90 days following their respective presentation dates.
About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; the creation of the next generation of life science tools; and as biologic therapeutics and in gene therapy. The Company’s unique enzymes drive improvements such as reduced energy usage, waste generation and capital utilization, higher yields, higher fidelity diagnostics, and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit www.codexis.com.
Investor Relations Contact:
Argot Partners
Stephanie Marks/Carrie McKim
(212) 600-1902
Codexis@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.